The case for HER2/neu as a therapeutic target for gynecologic malignancies

Immunotherapy

Volumn 4, Issue 8, 2012, Pages 781-784

  Goyne, Hannah E ^a   Cannon, Martin J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

carcinosarcoma; gynecologic cancer; HER2 neu; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CARCINOSARCOMA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; NATURAL KILLER CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; UTERUS CARCINOMA;

EID: 84865788910     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.71     Document Type: Article

References (13)

1. Guzzo F, Bellone S, Buza N et al. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int. J. Gynecol. Pathol. 31, 211-221 (2012).
2. Santin AD, Bellone S, Gokden M et al. Overexpression of HER2/neu in uterine serous papillary cancer. Clin. Cancer Res. 8, 1271-1279 (2002).
3. Santin AD, Bellone S, Siegel ER et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am. J. Obstet. Gynecol. 192, 813-818 (2005).
4. Raspollini MR, Susini T, Amunni G et al. COX-2, c-KIT and HER2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol. Oncol. 96, 159-167 (2005).
5. Sawada M, Tsuda H, Kimura M et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci. 94, 986-991 (2003).
6. Santin AD, Bellone S, van Stedum S et al. Amplification of c-erbB2 oncogene. A major prognostic indicator in uterine serous papillary carcinoma. Cancer 104, 1391-1397 (2005).
7. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer 16, 1897-1902 (2006).
8. Jewell E, Secord AA, Brotherton T, Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int. J. Gynecol. Cancer 16, 1370-1373 (2006).
9. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int. J. Gynaecol. Obstet. 102, 128-131 (2008).
10. Fleming GF, Sill MW, Darcy KM et al. Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 116, 15-20 (2010).
11. Garner WL, Minton JP, James AG, Hoffmann CC. Human breast cancer and impaired NK cell function. J. Surg. Oncol. 24, 64-66 (1983).
12. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by Herceptin in patients with gastric cancer. Cancer Res. 62, 5813-5817 (2002).
13. Kohrt HE, Houot R, Weiskopf K et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122, 1066-1075 (2012).